

# Corporate Fact Sheet

## OVERVIEW

Emergent BioSolutions offers specialized products to healthcare providers and governments to address medical needs and emerging health threats.



## OPERATIONS

- **Headquarters:** Rockville, MD
- **Manufacturing Facilities:** United States, Canada
- **Product Development Sites:** United States, Canada, Germany
- **Product Portfolio:** Vaccines and antibody therapeutics focused on infectious diseases, oncology, autoimmune diseases, and healthcare protective products
- **Services:** Contract manufacturing



12.5 acre Lansing, MI campus

## PORTFOLIO AS OF APRIL 2014

### BIODEFENSE PORTFOLIO

PRODUCT	DISEASE / THERAPEUTIC AREA	STAGE	TYPE
BioThrax® (Anthrax Vaccine Adsorbed)	Anthrax	Marketed	Vaccine
RSDL®	Chemical Decontamination	Marketed	Medical Device
VIGIV [Vaccinia Immune Globulin Intravenous (Human)]	Smallpox	Marketed	Therapeutic
BAT™ [Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)]	Botulism	Marketed	Therapeutic
PRODUCT CANDIDATE	DISEASE / THERAPEUTIC AREA	STAGE	TYPE
AIgIV [Anthrax Immune Globulin Intravenous (Human)]	Anthrax	Phase 3	Therapeutic
PreviThrax™ [Recombinant Protective Antigen Anthrax Vaccine, Purified]	Anthrax	Phase 2 <sup>1</sup>	Vaccine
NuThrax™ [Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant]	Anthrax	Phase 2 <sup>1</sup>	Vaccine
Thraxiva™ [Fully Human Anthrax Monoclonal Antibody]	Anthrax	Phase 1 <sup>1</sup>	Therapeutic
Additional preclinical programs focused on infectious diseases			

### BIOSCIENCES PORTFOLIO

PRODUCT	DISEASE / THERAPEUTIC AREA	STAGE	TYPE
WinRho® SDF [Rh <sub>0</sub> (D) Immune Globulin Intravenous (Human)]	Blood Disorder	Marketed	Therapeutic
HepaGam B® [Hepatitis B Immune Globulin Intravenous (Human)]	Hepatitis B	Marketed	Therapeutic
episil® [Oral Liquid] <sup>†</sup>	Oral Wound Dressing	Marketed	Medical Device
VARIZIG® [Varicella Zoster Immune Globulin (Human)]	Chickenpox	Marketed	Therapeutic
PRODUCT CANDIDATE	DISEASE / THERAPEUTIC AREA	STAGE	TYPE
Otlertuzumab (Humanized Anti-CD37 therapeutic*)	Chronic Lymphocytic Leukemia	Phase 2	Therapeutic
Additional preclinical therapeutic programs focused on oncology			

\* ADAPTIR™ – mono-specific protein therapeutics

<sup>1</sup> Status reflects both clinical and nonclinical development under the FDA Animal Rule

<sup>†</sup> Emergent BioSolutions holds a license from Camurus AB Corp. for sale in the United States of America (including all its possessions and territories)


## PLATFORM TECHNOLOGIES

PLATFORM TECHNOLOGY	DESCRIPTION	ROUTE	PRODUCT PIPELINE	
			CLINICAL	PRECLINICAL
<b>ADAPTIR™</b> (modular protein technologies) — <b>multi</b> -specific protein therapeutics	Scaffold for multi-specific molecules for the development of therapeutics	— Intravenous — Subcutaneous		— Anti-CD86xmono-IL10 Autoimmune and Inflammatory — Anti-CD3xanti-PSMA Oncology
— <b>mono</b> -specific protein therapeutics	Scaffold for mono-specific molecules for the development of therapeutics	— Intravenous — Subcutaneous	— Chronic Lymphocytic Leukemia	
<b>MVAator™</b> (modified vaccinia virus Ankara vector)	Recombinant, live, attenuated viral vector for the development of vaccines	— Injectable		— Respiratory Syncytial Virus (RSV) — Universal flu

## BUSINESS HIGHLIGHTS

- Completes Acquisition of CANGENE Corporation
- Positive Interim Phase 2 Data Evaluating Otlertuzumab in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia
- Otlertuzumab Shows Positive Results in Combination with Rituximab in People with CLL
- Closes on its Acquisition of Healthcare Protective Products Division from Bracco Diagnostics Inc.
- Advances Program Supporting Licensure of a Post-Exposure Prophylaxis Indication for BioThrax
- Receives Paul-Ehrlich-Institut Approval to Market BioThrax in Germany
- Presents Preclinical Efficacy Data on ES414; Its Lead ADAPTIR Bispecific Therapeutic for Prostate Cancer
- Presents Efficacy Data on ES210; a Bispecific ADAPTIR Molecule for Treating Autoimmune Diseases

## FINANCIAL HIGHLIGHTS



*Our historical results for any prior period are not necessarily indicative of results to be expected in any future period.*

### CONTACT INFORMATION

#### CORPORATE

2273 Research Boulevard, Suite 400  
Rockville, MD 20850 USA

Tel: 301-795-1800  
Fax: 301-795-1899

Business Development: [BD@ebsi.com](mailto:BD@ebsi.com)  
Investor Relations: [burrowsr@ebsi.com](mailto:burrowsr@ebsi.com)  
Corporate Communications: [schmittt@ebsi.com](mailto:schmittt@ebsi.com)  
[www.emergentbiosolutions.com](http://www.emergentbiosolutions.com)  
[www.biothrax.com](http://www.biothrax.com)  
[www.rsdecon.com](http://www.rsdecon.com)